Key Highlights
- Joey Dizenhouse’s appointment as President and CEO of SlateRx marks a significant step in the company’s journey towards innovating pharmacy benefits.
- Dizenhouse’s background includes over 25 years in healthcare and pharmacy benefits, including roles at HealthTrust and advisory positions with Fortune 100 companies.
- SlateRx’s partnership with HealthTrust aims to bring unique solutions to the challenges of rising pharmacy costs, leveraging Dizenhouse’s extensive experience and network.
Source: Business Wire
Notable Quotes
- “I am honored to lead an organization so committed to transparency and innovation in pharmacy benefits. Plan sponsors should be able to rely on a pharmacy benefit experience designed to truly protect those who receive care and those who pay for that care.” – Joseph M. Dizenhouse, FSA, MAAA, President & CEO at SlateRx
- “As this market continues to evolve, this will enable further value for HealthTrust members and growth of our world-class pharmacy program.” – Ed Jones, President and CEO at HealthTrust
- “Joey is a strong visionary healthcare leader and will help SlateRx execute its innovative PBX model—bringing together both PBM and PBA functions.” – Barry Katz, Board member at SlateRx
SoH's Take
The appointment of Joey Dizenhouse as President and CEO of SlateRx is a strategic move that could redefine the landscape of pharmacy benefits management. Dizenhouse’s deep-rooted experience in the healthcare sector, especially his tenure at HealthTrust, equips him uniquely to address the complexities and escalating costs associated with pharmacy benefits. His vision for transparency and innovation aligns with the current needs of the market, where stakeholders demand more accountability and efficiency in pharmacy benefit programs. The collaboration between SlateRx and HealthTrust under his leadership could set a new precedent in how pharmacy benefits are structured and delivered, potentially leading to more sustainable and cost-effective solutions for plan sponsors and beneficiaries. This move signifies a promising future for SlateRx and could be a game-changer in the pharmacy benefits sector.
